Seagen Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Epstein

Chief executive officer

US$58.6m

Total compensation

CEO salary percentage	0.3%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2yrs
Board average tenure	9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Epstein's remuneration changed compared to Seagen's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$649m
Dec 31 2022	US$59m	US$190k	-US$610m

Compensation vs Market: David's total compensation ($USD58.59M) is above average for companies of similar size in the MX market ($USD5.70M).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.

CEO

David Epstein (61 yo)

less than a year

Tenure

US$58,588,196

Compensation

Mr. David R. Epstein, B.Sc., M.B.A., serves as Chief Executive Officer and Director at Seagen Inc. since November 9, 2022. He served as an Independent Director at Senti Biosciences, Inc. since June 09, 202...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Epstein	CEO & Director	less than a year	US$58.59m	no data
Todd Simpson	Chief Financial Officer	17.8yrs	US$5.71m	0.063% $ 390.5m
Vaughn Himes	Chief Technical Officer	6.9yrs	US$4.54m	0.072% $ 445.6m
Jean I. Liu	Chief Legal Officer & Corporate Secretary	8.7yrs	US$5.95m	0.028% $ 170.0m
Charles Romp	Executive Vice President of Commercial U.S.	3.3yrs	US$5.03m	0.032% $ 193.9m
Roger Dansey	Chief Medical Officer and President of Research & Development	less than a year	US$36.39m	0.014% $ 83.8m
William Compton	Senior VP of Global Information Technology & CIO	less than a year	no data	no data
David Caouette	Vice President of Corporate Communications	no data	no data	no data
Matt Skelton	Vice President of Marketing	7.7yrs	no data	no data
Peggy Pinkston	Chief Human Resources Officer	less than a year	no data	no data
Natasha Hernday	Chief Business Officer	less than a year	no data	no data
Megan O'Meara	Head of Early Stage Development & VP	no data	no data	no data

2.0yrs

Average Tenure

61yo

Average Age

Experienced Management: SGEN *'s management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Epstein	CEO & Director	less than a year	US$58.59m	no data
John Orwin	Independent Director	9.5yrs	US$468.53k	0.015% $ 95.2m
David Gryska	Independent Director	18.3yrs	US$483.53k	0.026% $ 160.9m
Daniel Welch	Independent Director	16.1yrs	US$468.53k	0.0099% $ 61.0m
Felix Baker	Independent Chair of the Board	20yrs	US$528.53k	0.022% $ 136.4m
Ted Love	Independent Director	2.9yrs	US$471.03k	0.0025% $ 15.5m
Nancy Simonian	Independent Director	11.3yrs	US$474.53k	0.033% $ 206.0m
Alpna Seth	Independent Director	5.3yrs	US$471.03k	0.0069% $ 42.5m
Sandra Swain	Independent Director	less than a year	US$214.73k	no data

9.5yrs

Average Tenure

62yo

Average Age

Experienced Board: SGEN *'s board of directors are considered experienced (9.5 years average tenure).

Seagen Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021)

Seagen Inc. Revises Earnings Guidance for the Year 2022

Insufficient new directors

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Insufficient new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age